PMID- 24000992
OWN - NLM
STAT- MEDLINE
DCOM- 20150608
LR  - 20211021
IS  - 1533-0338 (Electronic)
IS  - 1533-0346 (Print)
IS  - 1533-0338 (Linking)
VI  - 13
IP  - 5
DP  - 2014 Oct
TI  - In vivo assessment of HER2 receptor density in HER2-positive tumors by 
      near-infrared imaging, using repeated injections of the fluorescent probe.
PG  - 427-34
LID - 10.7785/tcrtexpress.2013.600265 [doi]
AB  - HER2 overexpression and amplification of the HER2/neu gene have been found in 
      approximately 25% of invasive breast carcinomas. They are associated with a poor 
      prognosis and resistance to therapy in breast cancer patients. Up to now, 
      clinical evaluation of human epidermal growth factor receptor 2 (HER2) expression 
      is based on ex vivo methods (immunohistochemistry (IHC) or fluorescence in situ 
      hybridization (FISH) staining of biopsied tissue). Our goal is to realize "image 
      and treat" paradigm using targeted fluorescent probes to evaluate expression 
      levels of cell biomarkers responsible for cancer progression and to monitor the 
      efficacy of corresponding monoclonal antibody treatments. We used fluorescent 
      Affibody-based probes for in vivo analysis of HER2 receptors using near-infrared 
      optical imaging that do not interfere with binding of the therapeutic agents to 
      these receptors. We have analyzed two types of breast carcinoma xenografts with 
      significant differences in HER2 expression (31 and 21 according to 
      classification) in the mouse model. Using our kinetic model to analyze the 
      temporal variations of the fluorescence intensity in the tumor area after two 
      subsequent injections allowed us to assess quantitatively the difference in HER2 
      expression levels for two tumor types (BT-474 and MD-MBA-361). This result was 
      substantiated by ELISA ex vivo assays of HER2 expression in the same tumors.
FAU - Ardeshirpour, Yasaman
AU  - Ardeshirpour Y
AD  - NIH/National Institute of Child Health and Human Development, Building 9, 9 
      Memorial Drive, Bethesda, MD 20892. gandjbaa@mail.nih.gov.
FAU - Hassan, Moinuddin
AU  - Hassan M
FAU - Zielinski, Rafal
AU  - Zielinski R
FAU - Horton, Jason A
AU  - Horton J
FAU - Capala, Jacek
AU  - Capala J
FAU - Gandjbakhche, Amir H
AU  - Gandjbakhche AH
FAU - Chernomordik, Victor
AU  - Chernomordik V
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20130831
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
RN  - 0 (Fluorescent Dyes)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/*diagnosis/metabolism
MH  - Cell Line, Tumor
MH  - Female
MH  - *Fluorescent Dyes/administration & dosage
MH  - Humans
MH  - Injections, Intravenous
MH  - Mice, Nude
MH  - Neoplasm Transplantation
MH  - Receptor, ErbB-2/*metabolism
MH  - Spectroscopy, Near-Infrared
PMC - PMC4527379
COIS- Conflict of Interest: The authors declare that they have no conflict of interest.
EDAT- 2013/09/05 06:00
MHDA- 2015/06/09 06:00
PMCR- 2015/08/06
CRDT- 2013/09/05 06:00
PHST- 2013/09/05 06:00 [entrez]
PHST- 2013/09/05 06:00 [pubmed]
PHST- 2015/06/09 06:00 [medline]
PHST- 2015/08/06 00:00 [pmc-release]
AID - 10.7785_tcrtexpress.2013.600265 [pii]
AID - 10.7785/tcrtexpress.2013.600265 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2014 Oct;13(5):427-34. doi: 
      10.7785/tcrtexpress.2013.600265. Epub 2013 Aug 31.